Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.27
-1.23 (-4.82%)
At close: Mar 30, 2026, 4:00 PM EDT
23.81
-0.46 (-1.90%)
After-hours: Mar 30, 2026, 5:19 PM EDT
Damora Therapeutics Employees
Damora Therapeutics had 7 employees as of December 31, 2025. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$29,977,000
Market Cap
1.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 2 | 40.00% |
| Dec 31, 2024 | 5 | -8 | -61.54% |
| Dec 31, 2023 | 13 | -32 | -71.11% |
| Dec 31, 2022 | 45 | 5 | 12.50% |
| Dec 31, 2021 | 40 | 12 | 42.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Immunocore Holdings | 524 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 298 |
| Harmony Biosciences Holdings | 293 |
| Maze Therapeutics | 141 |
| Nanobiotix | 103 |
| Oculis Holding AG | 49 |
DMRA News
- 12 hours ago - Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors - GlobeNewsWire
- 11 days ago - Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million - GlobeNewsWire
- 6 weeks ago - Galecto Announces Pricing of $275 Million Underwritten Public Offering - GlobeNewsWire
- 3 months ago - Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - GLTO, MOVE: two penny stocks quadrupled today – but should you buy? - Invezz
- 5 months ago - Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029 - Benzinga